274 related articles for article (PubMed ID: 27989785)
1. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract][Full Text] [Related]
2. VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.
Song SH; Jeong IG; You D; Hong JH; Hong B; Song C; Jung WY; Cho YM; Ahn H; Kim CS
Int J Clin Exp Pathol; 2014; 7(11):7681-9. PubMed ID: 25550804
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.
Suzuki S; Dobashi Y; Hatakeyama Y; Tajiri R; Fujimura T; Heldin CH; Ooi A
BMC Cancer; 2010 Nov; 10():659. PubMed ID: 21118571
[TBL] [Abstract][Full Text] [Related]
5. Neovascularity as a prognostic marker in renal cell carcinoma.
Bauman TM; Huang W; Lee MH; Abel EJ
Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract][Full Text] [Related]
7. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.
Wang W; Qi L; Tan M; Zhang Z; Du J; Wei X; Yao X
Urol Oncol; 2015 Apr; 33(4):168.e17-27. PubMed ID: 25766258
[TBL] [Abstract][Full Text] [Related]
8. VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.
Eronat O; Onursever A; Suren D; Yildirim M; Kandemir O; Ali Kahya H
J BUON; 2016; 21(5):1250-1258. PubMed ID: 27837630
[TBL] [Abstract][Full Text] [Related]
9. The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.
Cumpănas AA; Cimpean AM; Ferician O; Ceausu RA; Sarb S; Barbos V; Dema A; Raica M
Anticancer Res; 2016 May; 36(5):2291-5. PubMed ID: 27127135
[TBL] [Abstract][Full Text] [Related]
10. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
13. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
14. Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis.
Saleeb RM; Brimo F; Farag M; Rompré-Brodeur A; Rotondo F; Beharry V; Wala S; Plant P; Downes MR; Pace K; Evans A; Bjarnason G; Bartlett JMS; Yousef GM
Am J Surg Pathol; 2017 Dec; 41(12):1618-1629. PubMed ID: 28984673
[TBL] [Abstract][Full Text] [Related]
15. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
16. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C; Farris AB; Maithel SK
Ann Surg Oncol; 2011 Nov; 18(12):3384-90. PubMed ID: 21590454
[TBL] [Abstract][Full Text] [Related]
19. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
20. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
